152 related articles for article (PubMed ID: 37920996)
1. PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems.
Muscatello LV; Gobbo F; Avallone G; Innao M; Benazzi C; D'Annunzio G; Romaniello D; Orioles M; Lauriola M; Sarli G
Vet Pathol; 2024 May; 61(3):393-401. PubMed ID: 37920996
[TBL] [Abstract][Full Text] [Related]
2. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Ligand 1; An Immunotarget for Renal Cell Carcinoma.
Chandrasekaran D; Sundaram S; N K; R P
Asian Pac J Cancer Prev; 2019 Oct; 20(10):2951-2957. PubMed ID: 31653140
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical investigation of PNL2 reactivity of canine melanocytic neoplasms and comparison with Melan A.
Giudice C; Ceciliani F; Rondena M; Stefanello D; Grieco V
J Vet Diagn Invest; 2010 May; 22(3):389-94. PubMed ID: 20453212
[TBL] [Abstract][Full Text] [Related]
7. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
[TBL] [Abstract][Full Text] [Related]
8. Comparative characterization of two monoclonal antibodies targeting canine PD-1.
Kocikowski M; Dziubek K; Węgrzyn K; Hrabal V; Zavadil-Kokas F; Vojtesek B; Alfaro JA; Hupp T; Parys M
Front Immunol; 2024; 15():1382576. PubMed ID: 38779661
[TBL] [Abstract][Full Text] [Related]
9. The mechanism of de novo expression of programmed cell death-ligand 1 in squamous cell carcinoma of the lung.
Igarashi T; Teramoto K; Ishida M; Hanaoka J; Daigo Y
Oncol Rep; 2017 Oct; 38(4):2189-2196. PubMed ID: 28791392
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
[TBL] [Abstract][Full Text] [Related]
11. Recurrent PDL1 expression and PDL1 (CD274) copy number alterations in breast implant-associated anaplastic large cell lymphomas.
Tabanelli V; Corsini C; Fiori S; Agostinelli C; Calleri A; Orecchioni S; Melle F; Motta G; Rotili A; Di Napoli A; Pileri SA
Hum Pathol; 2019 Aug; 90():60-69. PubMed ID: 31125630
[TBL] [Abstract][Full Text] [Related]
12. Podoplanin Expression in Canine Melanoma.
Ogasawara S; Honma R; Kaneko MK; Fujii Y; Kagawa Y; Konnai S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2016 Dec; 35(6):304-306. PubMed ID: 27918691
[TBL] [Abstract][Full Text] [Related]
13. Immune parameters associated with survival in metaplastic breast cancer.
Chao X; Liu L; Sun P; Yang X; Li M; Luo R; Huang Y; He J; Yun J
Breast Cancer Res; 2020 Aug; 22(1):92. PubMed ID: 32811533
[TBL] [Abstract][Full Text] [Related]
14. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Expression of Programmed Death Ligand 1(PDL1) in Endometrial Carcinoma and Its Relation to CD4 and CD8 Positive Immune Cells.
Salama ME; Khairy DA
Asian Pac J Cancer Prev; 2022 Jul; 23(7):2491-2496. PubMed ID: 35901358
[TBL] [Abstract][Full Text] [Related]
16. PD1/PDL1 expression is associated with increased TIM3 expression and tumor-infiltrating T lymphocytes in fibroblastic tumors.
Chen H; Liu H; Ai J; Du X; Sun Y; Xiao S
Clin Transl Oncol; 2022 Mar; 24(3):586-596. PubMed ID: 34741725
[TBL] [Abstract][Full Text] [Related]
17. Antigen expression in canine tissues, recognized by a monoclonal antibody generated against canine melanoma cells.
Oliver JL; Wolfe LG
Am J Vet Res; 1992 Jan; 53(1):123-8. PubMed ID: 1539903
[TBL] [Abstract][Full Text] [Related]
18. Immune regulation of canine tumour and macrophage PD-L1 expression.
Hartley G; Faulhaber E; Caldwell A; Coy J; Kurihara J; Guth A; Regan D; Dow S
Vet Comp Oncol; 2017 Jun; 15(2):534-549. PubMed ID: 26842912
[TBL] [Abstract][Full Text] [Related]
19. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
[TBL] [Abstract][Full Text] [Related]
20. E-Cadherin Expression in Canine Melanocytic Tumors: Histological, Immunohistochemical, and Survival Analysis.
Silvestri S; Porcellato I; Mechelli L; Menchetti L; Iussich S; De Maria R; Sforna M; Bongiovanni L; Brachelente C
Vet Pathol; 2020 Sep; 57(5):608-619. PubMed ID: 32578507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
